Format

Send to

Choose Destination
Am J Hematol. 2012 Jul;87(7):687-91. doi: 10.1002/ajh.23180. Epub 2012 Mar 31.

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Author information

1
Department of Leukemia, Division of Cancer Medicine, The University of Texas: MD Anderson Cancer Center, Houston, USA. ejabbour@mdanderson.org

Abstract

Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to one of long-term management, but treatment success is challenged with poor medication adherence. Many risk factors associated with poor adherence can be ameliorated by close monitoring, dose modification, and supportive care. Controlling risk factors for poor adherence in combination with patient education that includes direct communication between the health care team and the patient are essential components for maximizing the benefits of TKI therapy.

PMID:
22473898
DOI:
10.1002/ajh.23180
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center